International guidelines for the management of NSCLC patients strongly recommend reflex broad molecular profiling of all newly diagnosed AC cases and mostly agree that ALK, BRAF, ERBB2, KRAS, MET, NTRK, RET, and ROS1 must be included in testing panels [6,7,8]. The gene discussed is MET; the disease is non-small cell lung carcinoma.